anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inguinal hernia repair is a very common surgical operation. Both laparoscopic and robot-assisted operations are considered acceptable. However, there is no clear indication for a particular approach. No prospective trial has been conducted so far to establish superiority of one approach over the other. The Investigator believes each approach has unique characteristics and may offer advantages over the other in the right population group. The Investigator will randomly assign patients in two arms according to the surgical approach, whether laparoscopic or robot-assisted. The Investigator will collect preoperative characteristics, intraoperative variables, and postoperative outcomes. The Investigator will compare all variables to establish differences between the two groups.
The process of myocardial hypertrophy in hypertension can lead to excessive activation of oxidative stress. Lipoamide (ALM) has significant antioxidant and anti-inflammatory effects. This study aimed to investigate the effects of ALM on hypertension-induced cardiac hypertrophy, as well as explore its underlying mechanisms. We evaluated the effects of ALM on spontaneously hypertensive rats and rat cardiomyocytes treated with Ang II. We found that ALM was not effective in lowering blood pressure in SHR, but it attenuated hypertension-mediated cardiac fibrosis, oxidative stress, inflammation, and hypertrophy in rats. After that, in cultured H9C2 cells stimulated with Ang II, ALM increased the expression of antioxidant proteins that were decreased in the Ang II group. ALM also alleviated cell hypertrophy and the accumulation of ROS, while LY294002 partially abrogated these effects. Collectively, these results demonstrate that ALM could alleviate oxidative stress in cardiac hypertrophy, potentially through the activation of the PI3K/Akt-mediated Nrf2 signaling pathway.
Subjects will be asked to come to the Rutgers EOHSI clinical center (Piscataway, NJ) for 5 study visits. A physical exam to determine eligibility will be done at the first study visit. If the subject is healthy and able to produce a sputum sample, he/she will then be scheduled for 2 3-hour exposure visits, at least 2 weeks apart. One exposure will be to clean air and the other exposure will be to 0.2 ppm ozone. During the exposures, subjects will be requested to ride an exercise bicycle intermittently (approximately every 15 minutes). A follow-up visit for sputum collection will be scheduled either 24, 48, or 72 hours after each exposure visit. Blood and exhaled breath samples will also be collected at each visit.
In two PCNSL Expansion Cohorts (Part B), emavusertib in combination with ibrutinib will be administered in patients with PCNSL. In Cohort 1, emavusertib 100 mg BID will be administered with ibrutinib 560 mg QD consecutively in a 28-day cycle in approximately 6 to 9 patients. In Cohort 2, CA-4948 200 mg BID will be administered with ibrutinib in at least 9 patients.
The invention discloses a Miao ethnomedicine formula for treating hypotension. Each dose of the medicine is prepared from the following medicinal materials (by weight): 20-25 g of henry magnoliavine stem or root, 10-15 g of radices lithospermi and 25-30 g of jujube. The medicine provided by the invention is prepared by the following steps: adding the above medicinal materials into a decoction device and adding 800-1000 g of water, boiling with high heat, decocting with gentle heat for 20-30 min, cooling and removing slag. The medicine is taken three times a day and 250-300 g of the medicine is used for each time. The Miao ethnomedicine formula is a proved formula handed down from the Miao nationality. Through reasonable compatibility of the medicinal materials, the Miao ethnomedicine formula has effects of nourishing blood and dispersing blood stasis and regulating qi, and can be used for effectively treating hypotension. 15 days is a treatment course, and effective rate of a treatment course is 86%.
To provide patch support films that have drug barrier properties and extensibility with a simple configuration and are easy to peel off from a carrier layer.SOLUTION: Provided is a patch support film made of a resin with drug barrier properties. The entire film is composed of an undulating shape in the thickness direction, having a concave and convex structure that repeats concave and convex parts along the surface, the film thickness of the patch support film being 5 μm or more and 150 μm or less. The height difference between the concave part and the convex part is larger than the film thickness of the patch support film. The top of the convex part and the bottom of the concave part each forms a flat part having a flat cross section. The top of the convex part and the bottom of the concave part that are adjacent to each other connected by a slope part, and the angle formed by the top of the convex part and the continuous slope part in the cross section is 110 degrees or more and 150 degrees or less. The ratio (H/L) of the height difference H to the distance L between the bottoms of the adjacent concave part on the surface on the side where the convex part protrudes is 0.10 or more and 1.00 or less.SELECTED DRAWING: Figure 1
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for 81% of lung cancer cases, among which over 47% presented with distant metastasis at the time of diagnosis. Despite the introduction of targeted therapy and immunotherapy, enhancing the survival rate and overcoming the development of resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics and targets that can mitigate lung metastasis and investigate its effects on biomarkers, such as cellular metabolomics. In the current study, we investigated the role of cyproheptadine (CPH), an FDA-approved anti-histamine drug in lung metastasis in vitro and in vivo.
METHODS AND RESULTS: CPH showed potent cytotoxicity on different lung cancer cell lines in vitro. Moreover, CPH decreased invasion and migration of LLC1 and A549 cells in Matrigel invasion transwell and plate scratch assays. The in vivo LLC1 syngeneic lung cancer model found decreased number of metastatic nodules on the surface of lungs of Setd7 KO mice compared to SETD7 WT. CPH treatment resulted in decreased growth of LLC1 subcutaneous tumors compared to untreated SETD7 WT. Finally, metabolomic study of tumor tissues showed rewiring of metabolomic pathways and downregulation of amino acids, such as arginine, serine, and glycine) in Setd7 KO and WT treated with CPH compared to untreated Setd7 WT mice.
CONCLUSION: These findings identify CPH as a potential therapeutic agent to block metastasis in advanced NSCLC and suggest SETD7 as a potential target for the prevention of lung metastasis.
The invention discloses a preparation method of an ointment used for the peripheral nerve injury postoperative repair, and aims to solve the problem about the postoperative treatment of peripheral nerve injury. The preparation method is characterized in that the ointment is prepared from the following raw materials in weight: Solanum lyratum Thunb., Clerodendrum trichotomum Thumb., Rubus delavayi Franch., Erycibe obtusifolia Benth., Securinega suffruticosa ( Pal1.) Rehd., Polygonatum sibiricum Red., Ligustrum lucidum Ait., Atractylodes macrocephala Koidz., Cassia alata L., Viburnum foetidrm Wall., Amblystegium serpens (Hedw.)B.S.G. and Spatholobus suberectus Dunn. The preparation method comprises the following steps: (1) essential oil is extracted from Ligustrum lucidum Ait., Clerodendrum trichotomum Thumb. and Securinega suffruticosa ( Pal1.) Rehd. coarse powder for standby application; (2) Viburnum foetidrm Wall. and Amblystegium serpens (Hedw.)B.S.G. are smashed into fine powder for standby application; (3) water is added into Solanum lyratum Thunb., Rubus delavayi Franch., Erycibe obtusifolia Benth., Polygonatum sibiricum Red., Cassia alata L., Atractylodes macrocephala Koidz. and Spatholobus suberectus Dunn for decoction, and the filtrate is concentrated to reach the relative density of 1.1, so that the water extract is obtained; (4) the essential oil prepared in the step 1 and the fine powder prepared in the step 2 are added into the water extract prepared in the step 3, stirred uniformly and are concentrated to reach the relative density of 1.36. The clinical trial proves that the ointment used for treating the peripheral nerve injury postoperative repair and prepared through the preparation method has the characteristics of excellent curative effect and higher safety, and is worthy of clinical application and popularization.
INTRODUCTION: Previous studies identified some environmental and lifestyle factors independently associated with children respiratory health, but few focused on exposure mixture effects. This study aimed at identifying, in pregnancy and in childhood, combined urban and lifestyle environment profiles associated with respiratory health in children.
METHODS: This study is based on the European Human Early-Life Exposome (HELIX) project, combining six birth cohorts. Associations between profiles of pregnancy (38 exposures) and childhood (84 exposures) urban and lifestyle factors, identified by clustering analysis, and respiratory health were estimated by regression models adjusted for confounders.
RESULTS: Among the 1033 included children (mean ± standard-deviation (SD) age: 8.2 ± 1.6 years old, 47% girls) the mean ± SD forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) were 99 ± 13% and 101 ± 14%, respectively, and 12%, 12% and 24% reported ever-asthma, wheezing and rhinitis, respectively. Four profiles of pregnancy exposures and four profiles of childhood exposures were identified. Compared to the reference childhood exposure profile (low exposures), two exposure profiles were associated with lower levels of FEV1. One profile was characterized by few natural spaces in the surroundings and high exposure to the built environment and road traffic. The second profile was characterized by high exposure to meteorological factors and low levels of all other exposures and was also associated with an increased risk of ever-asthma and wheezing. A pregnancy exposure profile characterized by high exposure levels to all risk factors, but a healthy maternal lifestyle, was associated with a lower risk of wheezing and rhinitis in children, compared to the reference pregnancy profile (low exposures).
CONCLUSION: This comprehensive approach revealed pregnancy and childhood profiles of urban and lifestyle exposures associated with lung function and/or respiratory conditions in children. Our findings highlight the need to pursue the study of combined exposures to improve prevention strategies for multifactorial diseases such as asthma.
The invention discloses a pH-adjusted self-assembled antibacterial peptide, a preparation method and application thereof, wherein the sequence of the antibacterial peptide SAP is shown in SEQ ID No. 1. Designing histidine His functional beta-folded peptide containing hydrophobic amino acids Trp and Val, wherein His and Trp are respectively arranged at non-hydrogen bond sites adjacent to the beta-folded structure and are distributed in a diagonal form, other hydrogen bond sites are respectively distributed with equivalent His and Val, D Pro-Gly as beta-turn links the two ends of the peptide chain of the beta-sheet structure. Dissolving the freeze-dried powder of the antibacterial peptide in ultrapure water with the pH value of 6.0, and fully self-assembling the antibacterial peptide monomer into nano particles in the aqueous solution. The application of the antibacterial peptide in preparing the medicines for treating the Escherichia coli infectious diseases in the acidic environment. The antibacterial peptide has effective antibacterial action in an acidic environment, has low hemolytic toxicity and good salt ion stability, and overcomes the defect of low stability of natural antibacterial peptide.
Patients will be treated with acetonide triamcinolone 0.2% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the gel in the entire lesion three times/days.The number of points will be variable according to the lesion size.
Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36 and reduce ligand binding to these kinases at clinically achievable concentrations (≤0.9 µM).

Encorafenib inhibited in vitro growth of tumor cell lines expressing BRAF V600 E, D, and K mutations. In mice implanted with tumor cells expressing BRAF V600E, encorafenib induced tumor regressions associated with RAF/MEK/ERK pathway suppression.

Encorafenib and binimetinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared with either drug alone, coadministration of encorafenib and binimetinib resulted in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. Additionally, the combination of encorafenib and binimetinib delayed the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared to either drug alone. In a BRAF V600E mutant NSCLC patient-derived xenograft model in mice, coadministration of encorafenib and binimetinib resulted in greater anti-tumor activity compared to binimetinib alone, with respect to tumor growth inhibition. Increased tumor growth delay after dosing cessation was also observed with the coadmnistration compared to either drug alone.

In the setting of BRAF-mutant CRC, induction of EGFR-mediated MAPK pathway activation has been identified as a mechanism of resistance to BRAF inhibitors. Combinations of a BRAF inhibitor and agents targeting EGFR have been shown to overcome this resistance mechanism in nonclinical models. Coadministration of encorafenib and cetuximab had an anti-tumor effect greater than either drug alone, in a mouse model of colorectal cancer with mutated BRAF V600E.
It is said that active oxygen largely affects eye diseases. In particular, age-related macular degeneration is considered as a serious disease for which no therapeutic method has been established so far. A large amount of active oxygen is generated due to the concentration of light at the macula in the retina. It is estimated that damages due to the active oxygen are accumulated in the macula with aging, thereby resulting in the onset of macular degeneration. Medicinal compositions efficacious against these eye diseases are obtained by the combination of the recent results in Western medicine with traditional Chinese knowledge. These compositions contain as the fundamental main components animal livers, which have been employed as remedies for eye diseases for a long time, and vitamins and carotenoids having a strong effect of eliminating active oxygen from the human body. As the animal livers, use can be made of carp liver, mamushi pit viper liver and sheep liver. Examples of the antioxidants include vitamin C, vitamin E, astaxanthin and lycopene. It is favorable to add powdery blueberry concentrate having an effect of activating the re-synthesis of rhodopsin.
During the initial screening visit, the physician will obtain your medical history and perform a physical exam. If you pass the screening, you will be randomized into either Ultrasound-guided Percutaneous Tenotomy Technique or Open Surgical Debridement. It will be a 50% chance. It will be compared to flipping a coin.

Once you have been placed in your treatment group, your treatment will be scheduled. You will then undergo your procedure and provided referral for physical therapy. You will also have follow up appointments with your physician to monitor your progress at 3 week(visit 3), 5 weeks (visit 4), 3 months (visit 5) 6 month (visit 6), and 12 month (visit 7) time points. You will also be requested to complete two patient questionnaires about your progress at visits 3-7.
PURPOSE: The diagnostic workup for assessment of sleep disorders commonly involves overnight testing to assess sleep patterns and pathological events. So far, little is known about preferences for provision of home sleep tests to patients with sleep disorders. This study aims to close this gap by eliciting preferences for home sleep testing using a discrete choice experiment (DCE).
METHODS: A DCE with seven attributes of at-home sleep testing and three levels per attribute was developed using a fractional factorial design. Patients with and without previous sleep testing experience were recruited from two large sleep centers in Germany. Coefficients for attribute levels were calculated using a conditional logit model to estimate their influence on choice decisions and calculate the relative importance of each attribute.
RESULTS: 305 patients (54.5 ± 13,1 years, 65.3% male) were enrolled, and 288 surveys with complete data included for analysis. Attributes with greatest relevance were Waiting time to discuss sleep study results; Waiting time to conduct sleep study, and Sleep quality during measurement. Of lowest importance was Diagnostic accuracy of sleep study, followed by Effort to apply sleep study device. Significant heterogeneity in choice behavior was found, including differences by gender, willingness-to-pay for sleep studies, and previous experience with sleep studies. Preferred location for conducting sleep testing was at-home in 50.7% and in-lab in 46.9%.
CONCLUSIONS: Preferences and relative importance of home sleep test attributes vary among different subgroups. Considering those preferences can be important for clinicians and policymakers when designing care pathways and planning of testing policies for sleep disorders.
Hispanic women are 20% more likely to die of breast cancer than non Hispanic white women who are diagnosed at a similar age and stage. One reason for this disparity may be differences in post diagnosis dietary behaviors. In order to reduce this disparity, and to improve overall survivorship, culturally appropriate dietary interventions that teach women how to eat a diet high in fruits and vegetables and low in saturated fat need to be developed for Hispanic breast cancer survivors. The investigators propose to conduct a randomized controlled study (n=70, 35 per arm) to test the effects of the ¡Cocinar para su salud! program on changing dietary behaviors among Hispanic breast cancer survivors who have recently completed treatment. The ¡Cocinar para su salud! program is a 12 week course that provides hands on education and instruction in nutrition education, meal preparation, and food shopping in a group setting. All participants will be followed for a total of 12 months, have clinical assessments at baseline, 6 months, and 12 months, and monthly telephone contacts using motivational interview techniques.
PURPOSE: A composition containing Acorus calamus var. angustatus essential oil is provided to suppress proliferation of vascular smooth cells and to prevent or treat disease caused by vascular smooth muscle cell hyperproliferation. CONSTITUTION: A vascular smooth muscle cell proliferation inhibitor contains Acorus calamus var. angustatus essential oil as an active ingredient. The Acorus calamus var. angustatus essential oil is obtained by steam distillation or polar solvent using roots or leaves of Acorus calamus var. angustatus. The Acorus calamus var. angustatus essential oil contains 30-50 weight parts of methyl isoeugenol and 10-30 weight parts of cyclohexanone. The composition is used in the form of capsule, injection, soft capsule, granule, or tablet.
PURPOSE: To obtain a carcinostatic having wide and potent carcinostatic action, containing, as active ingredient, a cyclobutane derivative having specific structure. CONSTITUTION: This carcinostatic contains, as active ingredient, a (1R, 2R, 3S)cyclobutane derivative of formula I (B is a purine base R<4> is H or a protecting group) e.g. 9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutan-1-yl]-adenine}. The compound of formula I is obtained, for example, by reaction between a compound of formula II (X is an eliminable group) and a purine base such as adenine or guanine. It is preferable that the above reaction be carried out at room temperature to 170 deg.C using 1-5 equivalents of the purine base per equivalent of the compound of formula II. This carcinostatic can be orally, intravenously or percutaneously administered, its dose being normally 0.1-500mg/kg b.w. a day.
The pathogenesis of fibrosing alterations in the skin and other organ systems is not yet sufficiently understood and current therapeutic options are limited. Fibrosing diseases of the skin lead to a loss of function, which can subsequently be accompanied by serious impairments in quality of life, increased morbidity and ultimately increased mortality. There are currently only a few pharmacological and therapeutic approaches approved to prevent or ameliorate fibrosing diseases. Furthermore, tissue-specific versus common, non-organ-specific pathophysiological cellular and molecular mechanisms are not resolved. The development of new, cause-based and therefore likely more efficient therapeutic approaches is urgently needed. This represents a major challenge, but also opens up the opportunity for special contributions to improve this medically unsolved problem. Here we present important findings from recent years with a focus on the role of the immune response in fibrogenesis.
The present invention relates to a method for treating pulmonary alveolar proteinosis related to MARS gene mutations in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of supplementation of methionine and/or its derivatives. Pulmonary alveolar proteinosis related to mutations in the gene encoding the methionine tRNA synthetase is a severe, early-onset lung disease that also associates liver involvement, failure to thrive, and systemic inflammation. Inventors describe an infant affected by this disease who was successfully treated by oral methionine supplementation. After three months of treatment she was free of respiratory symptoms, inflammation and cholestasis resolved, and there was a catchup in growth. Her bronchoalveolar lavage fluid was free of extracellular lipoproteinaceous material. Functional assays on peripheral monocytes, initially altered, normalized. This study paves the way for similar strategies in other tRNA synthetase deficiencies.
Granulocyte anti-cancer therapy refers to a method in which healthy donor granulocytes with high cancer-killing activity are collected and infused into a specific cancer patient by matching, to achieve the therapeutic anticancer effect. In this proposed trial, up to 100 Subjects with advanced cancer can be entered. Potentially hundreds of healthy Donor-participants will be recruited. First, granulocyte donors will be identified via in-vitro assay of Cancer Killing Activity (CKA), which screens healthy Donor-participants for those with anticancer activity of more than 80%. Secondly, after donor-recipient blood matching, (2.0-5.0)x10\^10 granulocytes will be collected from each donor, accounting for about 1/10 of the human body. Each patient will be given a dose of (2.0-5.0)x10\^10 granulocytes from a different donor per week over a course of 5 doses (with an ideal total infusion of 2X10\^11 granulocytes). After each infusion, the patients will be monitored carefully for possible adverse events. If adverse events occur, the infusion can be slowed down or stopped until the adverse events can be managed. The trial will observe the subject's cancer 7, 30, 90 and 180 days after the last infusion. Target lesions, non-target lesions, and new lesions will be evaluated via medical imaging and tumor markers. The responses will be compared against the measurements at baseline.